Fecal microbiota transplantation for immune checkpoint inhibitors(FMT for ICI)
Phase 2
- Conditions
- Malignant tumors for which immune check point inhibitors are indications
- Registration Number
- JPRN-jRCTs041200003
- Lead Sponsor
- Ohmiya Naoki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with the agreement in a document
Exclusion Criteria
1.Difficulty in FMT
2.Allergy to drugs used
3.Judged as unsuitable by researchers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in fecal microbiota between responsive and unresponsive groups by immune check point inhibitors
- Secondary Outcome Measures
Name Time Method Response rate and disease control rate of immune check point hinhibitors after fecal microbiota transplantation<br>PD-L1 expression, tumor-infiltrating T lympohocytes, and tumor mutational burden of tumors<br>Surface markers of peripheral blood lymphocytes before and after fecal microbiota transplantation